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Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K
oxidase, affect stable warfarin dose requirements and time to therapeutic INR. CYP4F2
is part of the CYP4F gene cluster, which is highly polymorphic and exhibits a high degree
of linkage disequilibrium, making it difficult to define causal variants. Our objective was to
examine the effect of genetic variability in the CYP4F gene cluster on expression of the
individual CYP4F genes and warfarin response. mRNA levels of the CYP4F gene cluster
were quantified in human liver samples (n= 149) obtained from a well-characterized liver
bank and fine mapping of the CYP4F gene cluster encompassing CYP4F2, CYP4F11,
and CYP4F12 was performed. Genome-wide association study (GWAS) data from
a prospective cohort of warfarin-treated patients (n = 711) was also analyzed for
genetic variations across the CYP4F gene cluster. In addition, SNP-gene expression
in human liver tissues and interactions between CYP4F genes were explored in silico
using publicly available data repositories. We found that SNPs in CYP4F2, CYP4F11,
and CYP4F12 were associated with mRNA expression in the CYP4F gene cluster. In
particular, CYP4F2 rs2108622 was associated with increased CYP4F2 expression while
CYP4F11 rs1060467 was associated with decreased CYP4F2 expression. Interestingly,
these CYP4F2 and CYP4F11 SNPs showed similar effects with warfarin stable dose
where CYP4F11 rs1060467 was associated with a reduction in daily warfarin dose
requirement (∼1 mg/day, Pc = 0.017), an effect opposite to that previously reported
with CYP4F2 (rs2108622). However, inclusion of either or both of these SNPs in a
pharmacogenetic algorithm consisting of age, body mass index (BMI), gender, baseline
clotting factor II level, CYP2C9∗2 rs1799853, CYP2C9∗3 rs1057910, and VKORC1
rs9923231 improved warfarin dose variability only by 0.5–0.7% with an improvement
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in dose prediction accuracy of ∼1–2%. Although there is complex regulation across
the CYP4F gene cluster, the opposing effects between the two SNPs in the CYP4F
gene cluster appear to compensate for each other and their effect on warfarin dose
requirement is unlikely to be clinically significant.
Keywords: warfarin, pharmacogenetics, mRNA expression, CYP4F2, CYP4F11, CYP4F12
INTRODUCTION
The CYP4F gene subfamily comprises six members, namely
CYP4F2 (Kikuta et al., 1993), CYP4F3 (CYP4F3A and CYP4F3B)
(Kikuta et al., 1998), CYP4F8 (Bylund et al., 2000), CYP4F11 (Cui
et al., 2000), CYP4F12 (Bylund et al., 2001; Hashizume et al.,
2001), and CYP4F22 (Lefevre et al., 2006). Structurally, these six
CYP4F genes are largely similar, with more than 65% amino acid
sequence homology. To date, studies have focused on CYP4F2,
CYP4F3, CYP4F8, CYP4F11, and CYP4F12 while little is known
about the expression and function of CYP4F22. The splice sites of
CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12 are almost
identical, suggesting that this cluster of five genes may have
evolved by gene duplication (Bylund et al., 1999, 2001; Kikuta
et al., 1999; Cui et al., 2000).
CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12 reside
together on chromosome 19p13.1-2, spanning over 320 kb
(Supplementary Figure 1). These five members of the CYP4F
subfamily are all expressed in the liver and are known
for their roles in the metabolism of both endogenous and
exogenous compounds. They are involved in the catabolism
of substrates such as arachidonic acid and its oxygenated
derivatives (eicosanoids) such as leukotrienes, prostaglandins
(PGs), lipoxins, and hydroxyeicosatetraenoic acids (HETEs)
(Kikuta et al., 1999; Bylund et al., 2000, 2001; Hashizume
et al., 2001, 2002; Kalsotra et al., 2004), and they also catalyze
the metabolism of many drugs. For example, CYP4F2 has
also been implicated in the ω-hydroxylation of the tocopherol
phytyl side chain in the first step of vitamin E inactivation
(Sontag and Parker, 2002). In addition, CYP4F2 and CYP4F3B
have been shown to catalyze the initial O-demethylation of
the anti-parasitic prodrug pafuramidine by human liver and
intestinal microsomes (Wang et al., 2006, 2007). CYP4F2 has
also been reported to be a vitamin K oxidase and plays a
role in warfarin response (McDonald et al., 2009). CYP4F11 is
known to be active in the metabolism of several drugs including
erythromycin, benzphetamine, ethylmorphine, chlorpromazine,
and imipramine (Kalsotra et al., 2004). More recently, a study has
reported that CYP4F11 functions as a vitamin K ω-hydroxylase
(Edson et al., 2013). CYP4F12 has been reported to be involved
in the conversion of the antihistaminic prodrug ebastine to the
active drug carebastine by hydroxylation (Hashizume et al., 2001,
2002).
Warfarin is one of the most widely used oral anticoagulants
worldwide with proven efficacy in conditions characterized
by thromboembolism including atrial fibrillation, deep vein
thrombosis, pulmonary embolism, or heart valve prostheses.
Despite its efficacy, warfarin is often among the top three
drugs that lead to hospitalization from adverse drug reactions
(Budnitz et al., 2007; Wysowski et al., 2007), owing to
its narrow therapeutic window and large inter-individual
variability in dose response. Combinations of both non-genetic
and genetic factors influence the inter-individual variability
in warfarin therapeutic dose requirements. Genetic factors,
in particular, single nucleotide polymorphisms (SNPs) in
two genes responsible for warfarin pharmacokinetics and
pharmacodynamics – cytochrome P450 2C9 (CYP2C9) and
vitamin K epoxide reductase complex 1 (VKORC1) – have
repeatedly been found to be significantly associated with warfarin
responsiveness, explaining approximately 15 and 25% of dose
variability (Aithal et al., 1999; Yuan et al., 2005; Gage et al., 2008;
Wadelius et al., 2009; Schwanhausser et al., 2011), respectively.
Candidate gene(s) and GWAS studies have shown that the
CYP4F2 functional variant, rs2108622, accounts for a small
proportion of the variability in warfarin dose requirement (1–7%)
(Caldwell et al., 2008; Borgiani et al., 2009; Takeuchi et al.,
2009; Pautas et al., 2010). However, some studies have not
found an association between rs2108622 and warfarin stable
dose (Zhang et al., 2009; Perini et al., 2010). A functional study
utilizing human liver tissues did not find any association between
rs2108622 and CYP4F2 mRNA but observed a significant
association between the rs2108622 variant TT genotype and
lower microsomal CYP4F2 protein concentration and reduced
vitamin K1 oxidation, consistent with its function as a vitamin K1
oxidase in catalyzing the ω-hydroxylation of vitamin K1 phytyl
side chain (McDonald et al., 2009).
We have previously performed fine mapping of the CYP4F2
region to determine the influence of CYP4F2 SNPs and
haplotypes on various warfarin response outcomes (Zhang et al.,
2009). We found an association between rs2189784, a SNP in
strong linkage disequilibrium (LD) with rs2108622, with time to
achieve therapeutic International Normalized Ratio (INR), but
not with stable dose. Given the high degree of homology and LD
across the CYP4F gene cluster (Supplementary Figure 1), we have
undertaken a genotype–phenotype assessment utilizing a well-
characterized liver bank and a prospective patient cohort who
were followed up for 6 months from the time of intake of warfarin
(as summarized in Supplementary Figure 2). In silico analysis was
also performed to investigate additional SNP-gene associations
and the interactions between the CYP4F genes.
MATERIALS AND METHODS
Study Populations
Written informed consent in accordance with the Declaration of
Helsinki was obtained from all patients recruited to the following
cohorts.
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Liver Surgery Cohort
Blood and liver tissue samples were collected from 149 Caucasian
patients undergoing liver surgery at the Department of General,
Visceral, and Transplantation Surgery, Campus Virchow,
University Medical Centre Charité, Humboldt University, Berlin,
Germany, as described previously (Gomes et al., 2009). Normal
liver tissues were obtained from adjacent regions of surgically
removed liver tumors or metastases or hepatic tissue respected
for other reasons. All liver tissue samples were certified to be
free of malignant cells by pathological examination. None of
these samples were from patients with hepatitis, or cirrhosis,
or from those who had chronic alcohol abuse. Clinical patient
documentation for all samples included age, gender, medical
diagnosis, pre-surgical medication, alcohol use, and smoking.
The study was approved by the Research Ethics Committees
of the Medical Faculties of the Charité, Humboldt University,
Berlin, and of the University of Tuebingen, Tuebingen, Germany.
Warfarin-Treated Patient Cohort
Thousand patients starting warfarin therapy were recruited
prospectively at two hospitals in Liverpool, United Kingdom
(Royal Liverpool and Broadgreen University Hospitals Trust
and University Hospital Aintree). The main indications for
warfarin therapy were treatment of venous thromboembolism
and prophylaxis against systemic emboli in patients with atrial
fibrillation. The study was approved by the Birmingham South
Research Ethics Committee, United Kingdom.
Determination of CYP4F2, CYP4F8,
CYP4F11, and CYP4F12 mRNA
Expression Levels in Human Liver
RNA was extracted from the human liver tissue (n = 149) using
TRIzol R© reagent (Invitrogen, Paisley, United Kingdom) with
subsequent RNA clean-up using QIAGEN RNeasy-Mini Kit with
on-column DNase treatment. All RNA preparations were of high
quality with RNA integrity number (RIN) >7, as measured on the
Agilent Bioanalyzer (Nano-Lab Chip Kit, Agilent Technologies,
Waldbronn, Germany). Levels of gene expression of over
48,000 mRNA transcripts were assessed by the Human-WG6v2
Expression BeadChip (Illumina, Eindhoven, The Netherlands)
as previously described (Schroder et al., 2013). Pre-processing
and quality control of the expression data was conducted using
the Illumina BeadStudio, version 3.0 (Illumina, San Diego, CA,
United States) and the various steps involved are detailed in
Schroder et al. (2013). Probe signal intensities corresponding to
15,439 unique genes remain after all pre-processing steps and
the data set was log2 transformed. Probe sequences for CYP4F2,
CYP4F8, CYP4F11, and CYP4F12 were confirmed to be specific
and expression data were extracted. CYP4F3 and CYP4F22 were
not further analyzed due to ambiguous probe or gene annotation.
Liver Surgery Cohort: CYP4F2, CYP4F11, CYP4F12
SNP Selection, Genotyping, and Haplotype Analysis
Genomic DNA from the liver surgery patients (n = 149) was
extracted from whole blood using the QIAamp DNA Mini
Kit (QIAGEN GmbH, Hilden, Germany) according to the
manufacturer’s instructions.
Eighty genetic polymorphisms in the CYP4F2 gene were
selected as previously reported (Zhang et al., 2009). SNPs
encompassing CYP4F11 and CYP4F12 across the chromosomal
19p13.11 region were chosen on the basis of their functionality,
coverage in the CEU population (Utah residents with ancestry
from northern and western Europe) available on HapMap data
release 27, NCBI build 36 assembly, minor allele frequency
(MAF > 1%) and block-tagging ability (r2 ≥ 0.8). A total
of 130 SNPs in the CYP4F11 and CYP4F12 region were
successfully designed and subdivided into six multiplex
assays using Sequenom’s online Human GenoTyping Tools1.
Primer sequences are available on request. All SNPs were
genotyped using the Sequenom MassARRAY iPLEXTM platform
(Sequenom, Hamburg, Germany) in accordance with the
manufacturer’s instructions. To ensure data quality, 10% DNA
replicates and 8 negative controls (water) were included per
384-well plate during genotyping. Markers which deviated from
Hardy–Weinberg equilibrium (HWE, P < 0.001) (n = 10),
those with less than 90% call rate (n = 27), and those which
were monomorphic (n = 26), were excluded from downstream
analysis (see Supplementary Table 1).
The pattern of pairwise LD between the SNPs was visualized
using the program HaploView version 4.2 (Barrett et al., 2005).
Haplotype blocks were defined using the default algorithm
by Gabriel et al. (2002) in HaploView. The most probable
combinations of haplotype-pairs at each block were inferred
using the program PHASE version 2.1.1 (Stephens et al., 2001;
Stephens and Scheet, 2005). Any individuals with a haplotype-
pair probability of <90% (n = 11) for at least one haplotype
block were excluded from tests of association. Within a haplotype
block, haplotypes with frequencies <1% were grouped together as
a single covariate for analysis.
Warfarin-Treated Patient Cohort: Genome-Wide
Genotyping and Imputation
Genomic DNA was extracted from whole blood using the
standard phenol–chloroform method. Genome-wide genotyping
was performed using the Illumina Human610-Quad BeadChip
(Illumina, San Diego, CA, United States) at the Wellcome Trust
Sanger Institute, United Kingdom. Of the 1000 patients recruited,
genome-wide genotype data were available for 752 individuals as
previously described (Bourgeois et al., 2016). All quality control
measures were performed using PLINK (Purcell et al., 2007).
All SNPs with a genotyping success rate <95%, HWE threshold
of P < 0.0001 and those with MAF <1% were excluded from
the dataset. Cryptic relatedness was assessed between individuals
and one individual from each pair with an estimated identity by
descent (IBD) >0.1875 (i.e., halfway between the expected IBD
for third- and second-degree relatives) was removed. Subjects
with genotyping success rate <95% were also removed. Principle
component analysis was performed to assess genetic markers for
ethnicity. Only individuals with genetically matching ethnicity
were included into the association analysis (n= 711).
For the purpose of this study, genotype data for SNPs across
CYP4F2, CYP4F11, and CYP4F12 were extracted (n = 80)
1https://www.mysequenom.com/Tools
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for downstream analyses. After pre-phasing via SHAPEIT
(Delaneau et al., 2012), imputation of genotypes at additional
SNPs throughout the region encompassing CYP4F2, CYP4F11,
and CYP4F12 (chr19:15–17 Mb, B36) was carried out using
IMPUTE2 (Howie et al., 2009) with the reference genotype
data from the European 1000 Genomes Phase I data set
(release date June 2014). Imputed variants with an information
score <0.8, MAF <1%, HWE <0.0001 and genotyping success
rate <95% were excluded using QCTool, leaving a total of
1400 SNPs harboring the CYP4F12-CYP4F2-CYP4F11 genomic
region.
Statistical Analysis
Statistical analyses were conducted with the software package
SPSS, version 18. For each univariate test of association, two
tests were performed, one making no assumption on the mode
of inheritance while the other assumed an additive mode of
inheritance. The minimum P-value is referred to in each analysis.
All P-values from the genotype–phenotype association
tests undertaken in the functional and clinical studies were
independently adjusted for multiple testing using false discovery
rate (FDR) (Benjamini et al., 2001) in the genetics package of R,
version 3.1.22. FDR-corrected P-values are denoted as Pc-values
and values <0.05 were regarded as statistically significant.
The proportion of variability explained by the genetic
covariates was calculated using Nagelkerke’s R2 statistic
(Nagelkerke, 1991).
Liver mRNA Analysis
Relationships between each of the phenotypic parameters
evaluated were examined by Spearman correlation analysis. The
mRNA levels of the four CYP4F genes were not normally
distributed. To enable the use of parametric statistical tests, the
expression data were natural log transformed. To evaluate the
association of each SNP or haplotype with mRNA expression
levels, one-way analysis of variance (ANOVA) and univariate
linear regression were conducted.
Warfarin Outcome Analysis
Warfarin stable dose was defined as an unchanged daily dose at
three or more consecutive clinic visits where INR measurements
were within the individual’s target range (Jorgensen et al., 2009;
Zhang et al., 2009). As the distribution of stable dose was skewed,
the outcome was log transformed to achieve normal distribution.
To test for the association of SNPs with warfarin stable
dose, ANOVA and univariate linear regression were employed.
Conditional analysis was conducted by including the SNP of
interest into the linear regression model as a covariate. Dosing
algorithms were built by incorporating significant (P ≤ 0.05)
clinical and genetic variables from the univariate analyses into the
multiple linear regression models. Supplementary Table 3 reports
the significant results of the univariate analyses. To assess the
predictive accuracy of the dosing algorithms, the mean absolute
error was determined by calculating the average of the difference
between the predicted and actual stable doses. The percentage of
2http://cran.r-project.org/web/packages/genetics/index.html
predicted dose which fell within 20% of the actual maintenance
dose was also calculated.
In Silico Analysis to Identify SNPs
Associated with mRNA Expression
Putative expression quantitative trait loci (eQTLs) in the CYP4F
gene cluster were identified using the eQTL browser3, a database
that summarizes results from large-scale studies which identified
eQTLs in the liver (Schadt et al., 2008), brain (Myers et al.,
2007), fibroblasts (Dimas et al., 2009), T-cells (Dimas et al., 2009),
monocytes (Zeller et al., 2010), and lymphoblastoid cell lines
(Stranger et al., 2007; Veyrieras et al., 2008; Dimas et al., 2009;
Montgomery et al., 2010; Pickrell et al., 2010).
Network Building to Evaluate Interaction
between CYP4F2, CYP4F11, and
CYP4F12
The interactions between CYP4F2, CYP4F11, and CYP4F12
were visualized in MetaCoreTM (GeneGo, Inc., St. Joseph, MI,
United States), an interactive database derived from manually
curated literature publications on proteins and small molecules
of biological relevance in humans. Results are discussed
in the Supplementary Material (Supplementary Figure 3,
Supplementary Results, and Supplementary Discussion).
RESULTS
Correlation between Hepatic CYP4F
mRNA Expression Levels
The mRNA levels of the four CYP4F genes that were detected by
specific probes varied considerably between individuals, ranging
from an expression ratio of 2 for CYP4F8 to an expression ratio of
37 for CYP4F12 (Table 1). Significant correlations among the four
CYP4F genes are depicted in Figure 1. CYP4F11 and CYP4F12
mRNA showed significant albeit not very strong correlations with
CYP4F2 mRNA (rs = 0.25 and 0.384, respectively, P < 0.01;
Figures 1A,B) and with each other (rs = 0.3, P < 0.001;
Figure 1D). CYP4F8 expression was not significantly correlated
to any of the others.
3http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/
TABLE 1 | Variability of mRNA expression in the CYP4F gene cluster.
Gene n mRNA expression (arbitrary unit)
Range Ratio (maximum/minimum)
CYP4F2 149 0.21–2.22 10
CYP4F8 149 0.67–1.38 2
CYP4F11 149 0.35–2.53 7
CYP4F12 149 0.08–2.99 37
Normalized median mRNA expression for all genes = 1.00.
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FIGURE 1 | Statistically significant CYP4F mRNA correlations in 149 Caucasian human liver tissues. (A) CYP4F2 vs. CYP4F11; (B) CYP4F2 vs. CYP4F12;
(C) CYP4F8 vs. CYP4F11; (D) CYP4F11 vs. CYP4F12. vs., versus. The Spearman’s rho correlation coefficient (rs) and P-value for each comparison are given. Log2
transformed expression data are presented.
Genotype–Phenotype Correlation
between CYP4F2 Variants and Hepatic
mRNA Expression of the CYP4F Gene
Cluster
Associations between CYP4F2 variants and hepatic mRNA
expression of the CYP4F gene cluster are summarized in Table 2.
Contrary to a previous report (McDonald et al., 2009), we found
a significant association between rs2108622 and liver CYP4F2
mRNA expression (Figure 2C), with subjects homozygous for
the rs2108622 minor T allele showing greater CYP4F2 expression
compared to subjects homozygous for the major C allele
(TT = 1.47 ± 0.29, CC = 0.97 ± 0.31, Pc = 1.72 × 10−3,
R2 = 12.6%). Moreover, several other CYP4F2 variants were also
associated with significantly higher CYP4F2 expression including
rs2189784 (Pc = 0.030, R2 = 7.9%, Figure 2A), a SNP located
29 kb downstream of the CYP4F2 gene.
Interestingly, in addition to being associated with increased
CYP4F2 mRNA expression, rs2108622 demonstrated a
significant association with decreased CYP4F11 mRNA levels
(Pc = 6.06 × 10−4, R2 = 13.7%, Figure 2D) while rs2189784
was significantly associated with lower levels of CYP4F12 mRNA
expression (Pc = 0.031, R2 = 8.3%, Figure 2B). No associations
were found between CYP4F2 variants and CYP4F8 mRNA
expression (data not shown).
Genotype–Phenotype Correlation
between CYP4F11 and CYP4F12 SNPs
and Hepatic mRNA Expression of the
CYP4F Gene Cluster
Looking at the region encompassing the CYP4F gene cluster
on HapMap database (Supplementary Figure 1), high LD is
seen in the CYP4F12-CYP4F2-CYP4F11 locus, suggesting that
SNPs across the CYP4F11 and CYP4F12 regions could be
associated with mRNA expression of CYP4F2 and possibly
other CYP4F gene cluster members. To examine the genetic
contribution of variants in CYP4F11 and CYP4F12 on the hepatic
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FIGURE 2 | Levels of CYP4F2, CYP4F11, CYP4F12 mRNA in normal liver tissue donated from 149 patients in relation to corresponding SNPs across the
CYP4F2-CYP4F11 locus. (A,B) rs2189784; (C,D) rs2108622; (E,F) rs1060467. FDR-corrected P-values (Pc) are shown in the upper left corner. Each dot represents
an individual and the solid lines represent the mean values.
Frontiers in Pharmacology | www.frontiersin.org 7 May 2017 | Volume 8 | Article 323
fphar-08-00323 May 29, 2017 Time: 15:1 # 8
Zhang et al. Genotype–Phenotype Assessment of CYP4F12-CYP4F2-CYP4F11 Region
mRNA expression of the CYP4F gene cluster, fine mapping of
the CYP4F11 and CYP4F12 gene regions was conducted and
significant associations are summarized in Table 2.
rs1060467, a genetic variant located in the 3′ untranslated
region (UTR) of CYP4F11 demonstrated a significant association
with decreased CYP4F2 mRNA expression (Pc = 0.031,
R2 = 7.2%, Figure 2E); whilst an opposite trend for increasing
CYP4F11 mRNA expression was observed which was not
statistically significant after FDR (Pc = 0.310, Figure 2F).
Eight SNPs spanning CYP4F12 were significantly associated
with CYP4F12 mRNA expression. No significant association with
CYP4F8 mRNA expression was observed with any SNPs in the
CYP4F11 or CYP4F12 region (data not shown).
Association of Haplotypes in the
CYP4F12-CYP4F2-CYP4F11 Region on
Hepatic mRNA Expression of the CYP4F
Gene Cluster
To explore the complex genetic architecture of CYP4F locus
containing CYP4F2, CYP4F11 and CYP4F12, haplotypes across
these three genes were constructed based on the genotype data.
Ten haplotype blocks were identified as shown in Figure 3, with
details of haplotypes inferred and their estimated frequencies.
Effects of CYP4F2, CYP4F11, and CYP4F12 haplotypes on hepatic
mRNA expression of the CYP4F gene cluster were evaluated and
significant associations are reported in Table 3.
Haplotype 4A harboring the sequence ‘AT’ with a frequency
of 43.3% was associated with a significant increase in hepatic
CYP4F2 (Pc = 0.030, R2 = 7.9%; Figure 4A) and reduced
CYP4F12 (Pc = 0.030, R2 = 8.3%; Figure 4B) mRNA
expression, mirroring the effect of rs2189784. Corresponding
to the effect of rs2108622, haplotype 5A ‘TGCGGTGGG’
(frequency = 28.3%) was significantly associated with increased
CYP4F2 (Pc = 1.71 × 10−3, R2 = 12.6%; Figure 4C) and
decreased CYP4F11 (Pc = 5.96 × 10−4, R2 = 13.8%; Figure 4D)
mRNA expression. Resembling the effect of rs1060467, haplotype
8B (sequence ‘TGC,’ frequency = 33.2%) was associated with
down-regulation of CYP4F2 (Pc = 0.029, R2 = 7.0%; Figure 4E)
and showed a non-significant up-regulating effect on CYP4F11
(Pc = 0.350; Figure 4F) mRNA expression.
Competing Effects of CYP4F11
rs1060467 and CYP4F2 rs2108622 on
Warfarin Stable Dose
Linkage disequilibrium analysis of genotypes in our 149 livers
revealed that CYP4F11 rs1060467 and CYP4F2 rs2108622 were
moderately correlated with LD estimates of r2/D′ = 0.21/1.00. To
assess the roles of rs1060467 and rs2108622 in warfarin response,
we tested their association with the clinical outcome of warfarin
stable dose in our prospective cohort of warfarin-treated patients
(n = 711). Demographics of the 711 patients are summarized
in Table 4. Among the 711 patients investigated, 345 achieved
warfarin stable dose. Figure 5A illustrates warfarin stable
dose established in patients, stratified by CYP4F11 rs1060467
genotype. Patients with a C allele exhibited reduced stable dose
requirements (mg/day: TT = 4.6 ± 0.2, TC = 3.9 ± 0.1,
CC = 3.8 ± 0.2; Pc = 0.017). The proportion of warfarin
dose variability explained by rs1060467 was 2.6%. Conversely, as
depicted in Figure 5B, patients carrying the CYP4F2 rs2108622
T allele showed increased warfarin stable dose requirements
(mg/day: CC = 3.7 ± 0.1, CT = 4.3 ± 0.2, TT = 5.3 ± 0.4;
Pc = 0.003) and rs2108622 accounted for 4.3% of warfarin dose
variance.
By segregating the patients according to their haplotypes for
CYP4F2 rs2108622 and CYP4F11 rs1060467 as illustrated in
Table 5, it can be seen that there were small dose changes in
patients carrying haplotypes consisting of CYP4F2 rs2108622
wild-type genotype and CYP4F11 rs1060467 variant genotype
and vice versa.
Imputation and Conditional Analysis
To explore the presence of additional signals at the CYP4F loci,
genotype imputations were carried out across the 380 kb genomic
region encompassing the CYP4F12-CYP4F2-CYP4F11 region.
Although additional SNPs showed significant associations with
warfarin stable dose, the associations with CYP4F2 rs2108622 and
CYP4F11 rs1060467 remained the most significant among all the
CYP4F2 and CYP4F11 SNPs, respectively.
We also performed conditional analyses to evaluate the
independence of association between CYP4F2 rs2108622 and
CYP4F11 rs1060467. When we conditioned on CYP4F11
rs1060467, a reduction in both magnitude and significance was
seen with the association of warfarin stable dose with CYP4F2
rs2108622 (βinitial = 0.078, βconditional = 0.063, Pcinitial = 0.003,
Pcconditional = 0.05). When we conditioned on CYP4F2 rs2108622,
the association of warfarin stable dose with CYP4F11 rs1060467
disappeared (Pcinitial = 0.017, Pcconditional = 0.418). These results
suggest that CYP4F2 rs2108622 can explain the association signal
for CYP4F11 rs1060467 or vice versa.
Warfarin Dose Prediction Algorithms
To assess whether the inclusion of CYP4F2 rs2108622 and/or
CYP4F11 rs1060467 improves warfarin dose predictive accuracy,
we developed a clinical algorithm and several pharmacogenetic
algorithms as shown in Table 6. The clinical algorithm included
four predictors which were found significant in the univariate
analyses: age, BMI, gender and baseline clotting factor II
level, which explained 15.7% of warfarin dose variability.
The pharmacogenetic algorithm included CYP2C9∗2 rs1799853,
CYP2C9∗3 rs1507910, and VKORC1 rs9923231 genotypes in
addition to the clinical factors and accounted for a 32.3% increase
in warfarin dose variability, with a marked improvement in
dose prediction accuracy. The addition of CYP4F2 rs2108622 or
CYP4F11 rs1060467 to the pharmacogenetic algorithm explained
a further 0.5–0.7% in warfarin dose variability with a modest
increase in prediction accuracy (∼1% decrease in MAE and
1.2% increase in the number of predicted dose which fell within
±20% of the observed warfarin dose). When both rs2108622
and rs1060467 were incorporated into the pharmacogenetic
algorithm, there was a modest increase in the number of
predicted doses which fell within±20% of the observed warfarin
dose (∼2%).
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FIGURE 3 | Pairwise LD among polymorphisms in the region of CYP4F12-CYP4F2-CYP4F11 genes in 149 Caucasian samples (r2 ≥ 0.9). The left panel shows 10
distinct haplotype blocks defined by the confidence interval algorithm in HaploView 4.2 and the strength of LD is shown in increasing shades of gray, as depicted by
the bars. The right panel details the haplotypes sequences and their frequencies inferred by PHASE 2.1.
In Silico Genotype–Phenotype Analysis
To explore whether the SNP-gene effects observed in our
cohort of human livers was also present in other published
studies, we assessed eQTLs in the region encompassing CYP4F2,
CYP4F11, and CYP4F12 genes using the publicly available
eQTL database hosted by the Pritchard laboratories at the
University of Chicago. Table 7 outlines the significant SNP-
gene associations available on the eQTL database. Of particular
interest is the positive association of rs7248867, a SNP located
between CYP4F12 and CYP4F2, with CYP4F11 transcript
levels in livers from individuals of European descent. Using
genotype data available on HapMap, LD analysis revealed that
this intergenic SNP is in moderate LD with both rs2189784
(D′ = 1.0, r2 = 0.103) and rs2108622 (D′ = 1.0, r2 = 0.046).
rs7248867 also tags several SNPs (using r2 > 0.8) including
a CYP4F12 intronic SNP, rs2074568 (D′ = 1.0, r2 = 0.837)
which was analyzed in our cohort of 149 individuals who
had donated liver samples. rs2074568 showed a significant
association with increased hepatic CYP4F12 mRNA expression
(Pc = 1.49× 10−5) but not with CYP4F11 (P= 0.25) and CYP4F2
(P = 0.537).
Effect of Intergenic rs7248867 and
CYP4F12 rs2074568 on Warfarin Stable
Dose
Genotypes from the 1000 genomes project were imputed to
evaluate the effect of rs7248867 and rs2074568 on warfarin stable
dose. As illustrated in Figure 5C, patients carrying the minor
rs7248867 T-allele required lower warfarin doses compared to
patients carrying the major C-allele (mg/day: CC = 4.3 ± 0.1,
CT = 3.7 ± 0.2, TT = 3.2 ± 0.4; Pc = 0.009). The association of
rs2074568 was not significant after FDR but showed a recessive
effect on warfarin dose requirements (Figure 5D) with the minor
A-allele (mg/day: TT= 4.3± 0.1, TA= 3.7± 0.2, AA= 3.7± 0.6;
Pc = 0.061).
To assess the independence of these two SNPs to CYP4F2
rs2108622, conditional analyses were performed. When
conditioned on rs7248867, the association of CYP4F2 rs2108622
with warfarin stable dose decreased in both magnitude and
significance (βinitial = 0.078, βconditional = 0.065, Pcinitial = 0.003,
Pcconditional = 0.015). When we conditioned on rs2074568, a
reduction in magnitude and significance were also observed
with CYP4F2 rs2108622 (βconditional = 0.069, Pcconditional = 0.009).
These results suggest that rs7248867 and rs2074568 are correlated
with CYP4F2 rs2108622.
DISCUSSION
To elucidate whether the association between genotype and
gene expression reflected cis-acting regulatory effects on the
CYP4F gene cluster, we conducted a comprehensive investigation
looking at the effects of CYP4F2, CYP4F11, and CYP4F12
polymorphisms on the hepatic expression levels of CYP4F2,
CYP4F8, CYP4F11, and CYP4F12 mRNA in a Caucasian
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FIGURE 4 | Levels of hepatic CYP4F2, CYP4F11, CYP4F12 mRNA in normal liver tissue donated from 149 patients in relation to haplotypes across the
CYP4F2-CYP4F11 locus. (A,B) Haplotype 4A harboring sequence ‘AT’; (C,D) Haplotype 5A harboring sequence ‘TGCGGTGGG’; (E,F) Haplotype 8B harboring
sequence ‘TGC.’ FDR-corrected P-values (Pc) are shown in the upper left corner. Each dot represents an individual and the solid lines represent the mean values.
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TABLE 4 | Clinical profile of 711 warfarin patients.
Characteristic N (%)
Gender: male 394 (55.4)
Agea in years, mean (range) 69 (19− 95)





Atrial fibrillation 469 (66.0)
Pulmonary embolism 110 (15.5)
Deep vein thrombosis 74 (10.4)
Cerebrovascular accident and transient ischemic attacks 44 (6.2)
Mechanical heart valve replacement 8 (1.1)
Myocardial infarction 4 (0.6)
Dilated left atrium 2 (0.3)
Otherc 36 (5.1)
Co-morbidity
Cardiovascular disease 574 (80.7)
Musculoskeletal problems 426 (59.9)
Respiratory disease 268 (37.7)
Gastrointestinal disease 253 (35.6)
Neurological disease 156 (21.9)
Urological condition 132 (18.6)
Renal disease 75 (10.5)
History of falls 58 (8.2)
Hepatic disease 34 (4.8)
BMI, body mass index. aAge missing for nine patients. bBMI missing for six
patients. cOther indications include: prevention of clotting in arm for dialysis;
systemic lupus erythematosus; anti-phospholipid syndrome; short saphenous vein
thrombosis; valvular heart disease; saggital sinus thrombosis; dilated left ventrical;
occluded graft in leg; pulmonary hypertension; apical aneurysm; uticaria with
angiodema; femoral embolectomy; aortic and mitral regurgitation; ischemic colitis;
mitral stenosis; and post-surgery.
population. We report for the first time that SNPs and extended
haplotypes in CYP4F2, CYP4F11, and CYP4F12 affect the
mRNA expression levels of CYP4F2, CYP4F11, and CYP4F12 in
human liver tissues and that CYP4F11 plays a role in warfarin
response.
Unlike McDonald et al. (2009), our study observed a
significant association between the CYP4F2 rs2108622 SNP
and an increase in CYP4F2 mRNA expression, explaining
over 12% of the variability in CYP4F2 mRNA expression.
This may reflect our larger sample size (n = 149) of
livers compared with the previous study (McDonald et al.,
2009). Consistent with the fact that the CYP4F genes are
highly homologous and show extensive LD, our data show
that SNPs in one CYP4F gene can have an effect on
the expression of another CYP4F gene. In fact, rs2108622
in CYP4F2 was associated with decreased CYP4F11 mRNA
expression accounting for nearly 14% of CYP4F11 hepatic
mRNA expression. Comparatively, the haplotype harboring this
CYP4F2 variant also displayed similar associations. Conversely,
a variant in the 3′ UTR of the CYP4F11 region, rs1060467, was
associated with decreased CYP4F2 mRNA expression, accounting
for 7% of the variability in CYP4F2 mRNA expression. The
CYP4F11 haplotype comprising the minor rs1060467 C-allele
also had a corresponding recessive effect on CYP4F2 mRNA
expression.
Given these mutual genotype–phenotype relationships and
the fact that both CYP4F2 and CYP4F11 had been identified as
equally efficient vitamin K ω-hydroxylases (Edson et al., 2013),
we hypothesized that rs1060467 may play a role in warfarin
stable dose. Using our GWAS data previously conducted in
711 prospective patients on warfarin therapy, of which 345
patients achieved warfarin stable dose, rs1060467 explained
2.6% of warfarin dose variability, while rs2108622 accounted
for 4.3%, similar to previous reports (Caldwell et al., 2008;
Borgiani et al., 2009; Perez-Andreu et al., 2009). Interestingly,
the association of rs1060467 with warfarin dose was opposite to
that seen with rs2108622, confirming the compensatory effects
CYP4F2 and CYP4F11 polymorphisms have on hepatic CYP4F2
mRNA. However, when conditional analyses were performed
using SNP rs2108622, the magnitude and significance level
for rs1060467 were substantially attenuated, suggesting that
rs1060467 and rs2108622 are dependent loci and are both likely
to contribute to the same signal at the CYP4F2-CYP4F11 region.
Indeed, our pharmacogenetic algorithms incorporating CYP4F11
rs1060467 or CYP4F2 rs2108622 or both CYP4F11 rs1060467
and CYP4F2 rs2108622, explained a similar increase in warfarin
dose variability with modest improvement in prediction accuracy
(1–2%), indicating that just one of these SNPs can explain the
effect on warfarin dose variability. The opposing effects between
CYP4F11 rs1060467 and CYP4F2 rs2108622 in the CYP4F gene
cluster do not appear to affect warfarin dose requirement.
Our present study also showed a significant association of
rs2189784, a SNP located 30 kb downstream of CYP4F2, with
differences in mRNA expression of CYP4F2 and CYP4F12.
Interestingly, we have previously reported this SNP to play a
role in time taken to achieve therapeutic INR in patients on
prospective warfarin therapy (Zhang et al., 2009). Likewise, the
haplotype containing the minor A-allele of variant rs2189784
(haplotype 4A) was also significantly associated with increasing
CYP4F2 and decreasing CYP4F12 mRNA expression. These
results suggest that the previously observed association between
rs2189784 and time to therapeutic INR (Zhang et al., 2009) may
be mediated through an effect on CYP4F2 and CYP4F12 mRNA
and SNPs in CYP4F12 may affect CYP4F2 mRNA expression.
Evaluation of variants across the CYP4F12 region however,
did not show any SNPs to be associated with CYP4F2 mRNA
expression.
In silico eQTL analysis provided further insights into the
complexity of the regulation of the CYP4F gene cluster. CYP4F11
mRNA expression was associated with an intergenic SNP between
CYP4F12 and CYP4F2, rs7248867. This SNP is tagged by a
CYP4F12 intronic SNP (rs2074568) genotyped in our study.
These two SNPs were however, not present on the GWAS
platform. Imputations were therefore performed and a trend
for reduced warfarin stable dose was seen with these two SNPs.
However, our conditional analyses suggest that the association
signals found with rs7248867 and rs2074568 could be explained
by CYP4F2 rs2108622.
Frontiers in Pharmacology | www.frontiersin.org 12 May 2017 | Volume 8 | Article 323
fphar-08-00323 May 29, 2017 Time: 15:1 # 13
Zhang et al. Genotype–Phenotype Assessment of CYP4F12-CYP4F2-CYP4F11 Region
FIGURE 5 | Box and whisker plots showing the distribution of stable warfarin daily doses based on genotype groups in (A) CYP4F11 rs1060467; (B) CYP4F2
rs2108622; (C) intergenic rs7248867; (D) CYP4F12 rs2074568. Boxes represent 25th–75th percentiles of warfarin doses, whiskers represent 5th–95th percentiles,
and solid lines represent median dose in each group. Open dots represent outliers. FDR-corrected P-values (Pc) are shown on the upper right corner. Out of the 711
patients recruited prospectively, 345 achieved warfarin stable dose.
TABLE 5 | Relationship between CYP4F2 and CYP4F11 SNPs and stable warfarin
dose requirement∗.
Warfarin dose (mg/day)
CYP4F2 rs2108622 genotype CYP4F11 rs1060467 genotype
TT (n) CT and CC (n)
CC (n) 3.7 (162) 4.0 (18) 3.7 (144)
CT and TT (n) 4.4 (183) 4.7 (92) 4.0 (91)
∗Out of 711 patients recruited prospectively, 345 achieved warfarin stable dose.
A limitation of our study is that we did not investigate protein
expression levels of the different CYP4F isoforms. The reason
for this is that the protein sequences of CYP4F2, CYP4F11
and CYP4F12 share 81–93% similarity (Hirani et al., 2008) and
currently available antibodies are likely to exhibit high level of
cross-reactivity, decreasing the specificity of protein detection.
New technologies such as gene editing could be employed to
evaluate the function of these CYP4F genes.
CONCLUSION
We have effectively examined sequence variations across the
three CYP4F genes – CYP4F2, CYP4F11, and CYP4F12 and their
effect on mRNA expression. From a clinical perspective, our data
show the complexity of gene–gene interactions, where competing
effects of different SNPs within the same gene cluster can cancel
out the level of CYP4F2 mRNA and warfarin daily doses required
Frontiers in Pharmacology | www.frontiersin.org 13 May 2017 | Volume 8 | Article 323
fphar-08-00323 May 29, 2017 Time: 15:1 # 14
Zhang et al. Genotype–Phenotype Assessment of CYP4F12-CYP4F2-CYP4F11 Region
TABLE 6 | Comparison of predicted stable warfarin doses to actual stable warfarin doses using different prediction algorithms.
Prediction algorithm∗ Variables included MAE ± SE (mg/week) R2 Adj (%) Within ± 20% of
observed dose (%)
Clinical Age, BMI, Gender, Baseline Factor II 9.08 ± 1.06 15.7 43.7
Clinical + CYP2C9∗2 + CYP2C9∗3 +
VKORC1
Age, BMI, Gender, Baseline Factor II, rs1799853,
rs1057910, rs9923231
7.32 ± 0.88 48.0 47.3
Clinical + CYP2C9∗2 + CYP2C9∗3 +
VKORC1 + CYP4F2
Age, BMI, Gender, Baseline Factor II, rs1799853,
rs1057910, rs9923231, rs2108622
7.26 ± 0.88 48.5 48.5
Clinical + CYP2C9∗2 + CYP2C9∗3 +
VKORC1 + CYP4F11
Age, BMI, Gender, Baseline Factor II, rs1799853,
rs1057910, rs9923231, rs1060467
7.24 ± 0.88 48.7 48.5
Clinical + CYP2C9∗2 + CYP2C9∗3 +
VKORC1 + CYP4F2 + CYP4F11
Age, BMI, Gender, Baseline Factor II, rs1799853,
rs1057910, rs9923231, rs2108622, rs1060467
7.22 ± 0.88 48.6 49.4
∗Of the 345 patients who achieved stable warfarin dose, data on age, BMI and CYP2C9∗2 rs1799853 were missing for 4, 3, and 2 individuals, respectively. Therefore
only 336 patients were included in the prediction algorithms above. BMI, body mass index; MAE, mean absolute error; SE, standard error; R2 Adj, adjusted coefficient of
determination.
TABLE 7 | Expression quantitative trait loci (eQTLs) in the CYP4F12-CYP4F2-CYP4F11 gene cluster region.
SNP SNP localization SNP chromosomal location Target eQTL gene P-value Tissue Study
rs7246556 5′ upstream of CYP4F12 15637511 SLC35E1 9.75439E-05 Monocytes [52]
rs4808351 5′ upstream of CYP4F12 15638714 SLC35E1 6.21012E-05 Monocytes [52]
rs4807967 5′ upstream of CYP4F12 15638931 SLC35E1 6.21012E-05 Monocytes [52]
rs4808352 5′ upstream of CYP4F12 15638996 SLC35E1 0.00011855 Monocytes [52]
rs10409673 5′ upstream of CYP4F12 15640453 SLC35E1 6.21012E-05 Monocytes [52]
rs7251084 5′ upstream of CYP4F12 15641041 SLC35E1 6.21012E-05 Monocytes [52]
rs7259028 5′ upstream of CYP4F12 15641245 SLC35E1 6.21012E-05 Monocytes [52]
rs7248867 Intergenic, between CYP4F12 and CYP4F2 15731204 CYP4F11 8.23E-05 Liver [49]
rs2074901 CYP4F2 15858422 BRD4 1.80053E-05 Monocytes [52]
rs2074902 CYP4F2 15869099 BRD4 1.80053E-05 Monocytes [52]
rs1060463 CYP4F11 15886176 ILVBL 9.96552E-05 Monocytes [52]
rs6512075 CYP4F11 15899334 ILVBL 9.96552E-05 Monocytes [52]
rs3746154 CYP4F11 15899390 ILVBL 9.96552E-05 Monocytes [52]
rs3746156 CYP4F11 15896494 ILVBL 9.96552E-05 Monocytes [52]
rs2219358 CYP4F11 15896517 ILVBL 9.96552E-05 Monocytes [52]
rs2305803 CYP4F11 15888067 ILVBL 9.96552E-05 Monocytes [52]
rs17641483 5′ upstream of CYP4F11 15919371 CYP4F11 6.40767E-13 Monocytes [52]
Chromosomal positions are given in base pairs from the p-telomere of chromosome 19, as per HapMap Data release 27, NCBI B36 assembly, dbSNP b126. BRD4,
bromodomain containing protein 4; ILVBL, acetolactate synthase-like protein; SLC35E1, solute carrier family 35, member E1.
to maintain anticoagulation. As a result, the overall effect of SNPs
in CYP4F2 and CYP4F11 on warfarin dose variability is very small
in our population. However, in other populations with different
linkage patterns the influence of CYP4F SNPs may be larger. It is
possible that additional variants which are rare and functionally
active may be important other than the SNPs genotyped in our
study, and resequencing of the CYP4F2, CYP4F11 and CYP4F12
genes in appropriately phenotyped patients on warfarin may help
identify these.
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